IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)—The IKF-IMMULAB trial. Trastuzumab ...

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...

Testicular germ cell tumor survival among children, adolescents, and young adults: A population-based retrospective cohort study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.